PTG-300

PTG-300 is a hepcidin mimetic, a peptide hormone primarily produced by the liver that regulates iron homeostasis.

• Ferroportin binding: Binds to the iron transporter ferroportin on the surface of enterocytes, macrophages, and hepatocytes.
• Internalization and degradation: Promotes endocytosis and lysosomal degradation of ferroportin, blocking cellular iron export.
• Reduction of serum iron: Decreases intestinal iron absorption and release of stored iron, reducing transferrin saturation and ferritin levels.
• Erythropoietic modulation: In beta-thalassemia, improves ineffective erythropoiesis by limiting iron availability for free radical formation and oxidative stress.

• Hereditary hemochromatosis: Reduces transferrin saturation and ferritin levels, offering an alternative to therapeutic phlebotomy.
• Beta-thalassemia: Improves ineffective erythropoiesis and reduces the need for blood transfusions in transfusion-dependent thalassemia patients.
• Other iron overload conditions: Potential use in disorders such as sideroblastic anemia or secondary iron overload from chronic transfusions.

PTG-300 effectively reduces transferrin saturation and serum ferritin levels in patients with hereditary hemochromatosis, maintaining iron levels within the normal range with weekly administration. In beta-thalassemia, it improves erythropoietic parameters, reduces splenomegaly, and decreases transfusion needs. The most common adverse effects include injection site reactions (erythema, pain, swelling), headache, fatigue, and mild nausea. No serious adverse effects have been reported in clinical trials to date, but monitoring of iron levels is required to avoid hypoferremia.

PTG-300 is contraindicated in patients with known hypersensitivity to the active substance or any excipients. It is not recommended in patients with untreated iron deficiency anemia or active infections, as hepcidin may exacerbate anemia of chronic disease. Transferrin saturation and ferritin levels should be monitored periodically to adjust the dose and avoid hypoferremia. The most common adverse effects are mild and transient, but patients should be informed about the possibility of injection site reactions. There are insufficient data on its use during pregnancy or breastfeeding; therefore, it should be avoided in these populations unless the benefit clearly outweighs the risk. Patients with severe renal or hepatic impairment should be carefully evaluated before starting treatment.

PTG-300 (rusfertide) is currently in clinical research. It has completed phase 2 trials for hereditary hemochromatosis and beta-thalassemia, with promising results. It has not been approved by any regulatory agency (FDA, EMA) for commercial use. Phase 3 trials are planned or ongoing to confirm its efficacy and safety.

In clinical trials, PTG-300 is administered subcutaneously once weekly. The typical dose in phase 2 studies was 60 mg weekly, adjustable based on transferrin saturation and ferritin response. No established dose for use outside research.

Store refrigerated between 2°C and 8°C. Do not freeze. Protect from light. Once reconstituted, use within 24 hours if kept refrigerated. Do not shake vigorously.